PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
132 hedge funds and large institutions have $310M invested in PDL BioPharma, Inc. in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 49 reducing their positions, and 26 closing their positions.
287% more call options, than puts
Call options by funds: $302K | Put options by funds: $78K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11% more capital invested
Capital invested by funds: $279M → $310M (+$30.8M)
3% less funds holding
Funds holding: 136 → 132 (-4)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
41% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 49
Top Buyers
Top Sellers
PDLI Hedge Fund Activity: Q3 2020 in Review
132 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2020, worth a combined $310M — up 11% from $279M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PDLI and 23 opened new positions — a net loss of 3 holders — while 49 trimmed existing stakes and 29 added.
The largest buyer was Park West Asset Management, opening a new position worth an estimated $29.3M. The largest seller was Engine Capital Management, exiting entirely with an estimated $7.79M sold.
- 132 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2020, down from 136 in Q2 2020.
- Funds reported $310M of PDL BioPharma, Inc. stock for Q3 2020, up 11% quarter-over-quarter.
- 23 funds opened new PDL BioPharma, Inc. positions in Q3 2020 and 26 closed out, a net change of -3 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2020 was Park West Asset Management, an estimated $29.3M added.
- The largest PDL BioPharma, Inc. seller in Q3 2020 was Engine Capital Management, an estimated $7.79M sold.
Based on aggregated 13F filings for Q3 2020.